The role of autoantibody‐producing plasma cells in immune thrombocytopenic purpura refractory to rituximab
M Kuwana, S Iki, A Urabe - American journal of hematology, 2007 - Wiley Online Library
M Kuwana, S Iki, A Urabe
American journal of hematology, 2007•Wiley Online LibraryRituximab is becoming popular as a treatment for immune thrombocytopenic purpura (ITP).
We report here a patient with ITP, who initially responded to rituximab, but later became
refractory. In this patient, the appearance of plasma cells producing anti‐platelet
autoantibodies is likely to be one of the mechanisms for rituximab resistance. Am. J.
Hematol., 2007.© 2007 Wiley‐Liss, Inc.
We report here a patient with ITP, who initially responded to rituximab, but later became
refractory. In this patient, the appearance of plasma cells producing anti‐platelet
autoantibodies is likely to be one of the mechanisms for rituximab resistance. Am. J.
Hematol., 2007.© 2007 Wiley‐Liss, Inc.
Abstract
Rituximab is becoming popular as a treatment for immune thrombocytopenic purpura (ITP). We report here a patient with ITP, who initially responded to rituximab, but later became refractory. In this patient, the appearance of plasma cells producing anti‐platelet autoantibodies is likely to be one of the mechanisms for rituximab resistance. Am. J. Hematol., 2007. © 2007 Wiley‐Liss, Inc.
Wiley Online Library